Does a high arachidonic acid to EPA ratio reflect less EPA buffering of inflammatory signaling?

The balance between arachidonic acid (AA) and eicosapentaenoic acid (EPA) is a critical determinant of cellular inflammatory tone, governing the production of key lipid mediators.

Biochemical mechanisms

• Enzymatic competition: Both AA and EPA utilize the same enzymatic machinery, primarily cyclooxygenases (COX-1/COX-2) and lipoxygenases (such as 5-LOX). EPA directly competes with AA for these catalytic sites, binding to COX-1 with low-micromolar affinity ($K_m$) to act as a competitive inhibitor of AA metabolism.
• Alternative eicosanoid production: When EPA successfully competes for these enzymes, metabolic flux shifts away from highly active, pro-inflammatory AA-derived 2-series prostaglandins (PGE2) and 4-series leukotrienes (LTB4). Instead, the enzymes generate 3-series prostaglandins (PGE3) and 5-series leukotrienes (LTB5), which possess significantly lower inflammatory potency.

Clinical and physiological implications

• Unbuffered inflammatory signaling: An elevated AA/EPA ratio indicates a cellular environment with insufficient EPA to buffer AA signaling. This state of reduced competitive inhibition is associated with elevated levels of systemic pro-inflammatory cytokines, including IL-6 and TNF-α.
• Limitations of total omega-3 metrics: This enzymatic imbalance can persist even when an individual's total Omega-3 Index appears adequate. Because the standard index pools EPA and docosahexaenoic acid (DHA)—and DHA does not replicate EPA's precise competitive inhibition of COX and LOX pathways—a high AA/EPA ratio can still leave inflammatory cascades unchecked.

Bottom line

• The AA/EPA ratio is a precise, independent indicator of cellular inflammatory potential. Standard omega-3 metrics can mask a critical deficit in EPA-mediated enzymatic buffering, leaving pro-inflammatory arachidonic acid signaling unmitigated even when total omega-3 levels appear sufficient.